Division of Pulmonary and Critical Care Medicine and Mayo Clinic Center for Tuberculosis, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA,
Lung. 2015 Feb;193(1):3-11. doi: 10.1007/s00408-014-9655-9. Epub 2014 Oct 16.
The objective of this study is to compare how likely positive tuberculin skin test (TST) and T-SPOT(®).TB (TSPOT) results predict risk factors for tuberculosis in a predominantly immigrant patient population at risk of latent TB infection (LTBI) and with rheumatologic conditions requiring immunomodulatory therapy (IMT).
Prospective study conducted at a referral rheumatology clinic. Inclusion criteria included patients on various IMT, including immunosuppressive drugs that could predispose to TB progression. We studied risk factors associated with LTBI, test results, and tests' agreement.
We studied 101 patients. Eighty (79.2 %) were from countries where TB is prevalent and Bacille Calmette-Guérin vaccination is placed routinely. Seventy-four (73.3 %) had rheumatoid arthritis and 92 (90.7 %) were on IMT. Among patients with both TST and TSPOT results, 25 (30.9 %) were TST(+) and 20 (24.7 %) had TSPOT(+) results. Fifteen patients (18.5 %) had TST(+)/TSPOT(+) results, and 51 (63.0 %) had TST(-)/TSPOT(-) results (agreement = 81.5 %; kappa = .54 [95 % CI, .34-.74; P < .001]). Each TSPOT(+) and TST(+) results were independently associated with immigrant status and prior residence in a TB prevalent country after adjustment for immunosuppressive therapy: Adjusted OR(TSPOT+)=6.6 (95 % CI, 1.2-123.3; P = .027); and adjusted OR(TST+)=11.2 (95 % CI, 2.0-209.5; P = .003). Seven out of 10 TST(+)/TSPOT(-) cases had a TST ≥15 mm induration, including three cases with history of TST conversion.
TST(+) and TSPOT(+) results predict risk factors associated with LTBI independent of immunosuppressive IMT. Some TST(+)/TSPOT(-) results were unlikely to be false-negatives. The combined use of TST and TSPOT appears to be a reasonable diagnostic strategy to evaluate for LTBI in this population.
本研究旨在比较结核菌素皮肤试验(TST)和 T-SPOT(®).TB(TSPOT)结果在潜伏性结核感染(LTBI)风险较高且需要免疫调节治疗(IMT)的以移民为主的患者人群中预测结核病风险因素的可能性。
在转诊风湿病诊所进行的前瞻性研究。纳入标准包括接受各种 IMT 的患者,包括可能导致 TB 进展的免疫抑制药物。我们研究了与 LTBI 相关的危险因素、检测结果以及检测结果的一致性。
我们研究了 101 名患者。其中 80 名(79.2%)来自结核病流行且常规接种卡介苗的国家。74 名(73.3%)患有类风湿关节炎,92 名(90.7%)接受 IMT。在同时进行 TST 和 TSPOT 检测的患者中,25 名(30.9%)TST(+),20 名(24.7%)TSPOT(+)。15 名患者(18.5%)TST(+)/TSPOT(+),51 名患者(63.0%)TST(-)/TSPOT(-)(一致性=81.5%;kappa=0.54 [95%CI,0.34-0.74;P<0.001])。调整免疫抑制治疗后,每个 TSPOT(+)和 TST(+)结果均与移民身份和既往结核病流行国家居住史独立相关:调整后的 TSPOT(+)比值比(OR)=6.6(95%CI,1.2-123.3;P=0.027);调整后的 TST(+)比值比(OR)=11.2(95%CI,2.0-209.5;P=0.003)。在 10 例 TST(+)/TSPOT(-)病例中,有 7 例 TST 硬结≥15mm,其中 3 例有 TST 转化史。
TST(+)和 TSPOT(+)结果预测与 LTBI 相关的风险因素独立于免疫抑制 IMT。一些 TST(+)/TSPOT(-)结果不太可能是假阴性。TST 和 TSPOT 的联合使用似乎是评估该人群 LTBI 的合理诊断策略。